Global Epirubicin Hydrochloride Market Research Report 2022

Epirubicin Hydrochloride is the hydrochloride salt of the 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin. Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.
Due to the COVID-19 pandemic, the global Epirubicin Hydrochloride market size is estimated to be worth US$ 253.2 million in 2021 and is forecast to a readjusted size of US$ 211.1 million by 2028 with a CAGR of -2.5% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Epirubicin Hydrochloride market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Epirubicin Hydrochloride landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Global core Epirubicin Hydrochloride players include Synbias Pharma, Zhejiang Hisun Pharma and Pfizer etc. The top 3 companies hold a share about 60%. Asia-Pacific is the largest market, with a share about 45%, followed by Europe and North America with the share about 25% and 20%.
In terms of product, 10mg/5ml is the largest segment, with a share about 45%, followed by 50mg/25ml, with a share about 40%. And in terms of application, the largest application is cancer, with a share about 95%, followed by others, with a share about 5%.
This report focuses on Epirubicin Hydrochloride volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Epirubicin Hydrochloride market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China, Japan, India and Middle East and Africa, etc.
Global Epirubicin Hydrochloride Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Package and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Package
10mg/5ml
50mg/25ml
Other
Segment by Application
Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Sterling Biotech
Zhejiang Hisun Pharma
Flavine
Teva API
Microbiopharm Japan
DZD Heze Pharma
Synbias Pharma
Intas Pharma
Humble Healthcaare
Lunan Pharmaceutical Group
Pfizer
Beijing Union Pharmaceutical Factory

Frequently Asked Questions